HK1146065A1 - Nlrr-1 antagonists and uses thereof nlrr-1 - Google Patents

Nlrr-1 antagonists and uses thereof nlrr-1

Info

Publication number
HK1146065A1
HK1146065A1 HK11100147A HK11100147A HK1146065A1 HK 1146065 A1 HK1146065 A1 HK 1146065A1 HK 11100147 A HK11100147 A HK 11100147A HK 11100147 A HK11100147 A HK 11100147A HK 1146065 A1 HK1146065 A1 HK 1146065A1
Authority
HK
Hong Kong
Prior art keywords
nlrr
antagonists
Prior art date
Application number
HK11100147A
Other languages
English (en)
Chinese (zh)
Inventor
Victoria Smith
Jo-Anne S Hongo
Susanna Stinson
Meredith Hazen
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of HK1146065A1 publication Critical patent/HK1146065A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK11100147A 2007-10-02 2011-01-07 Nlrr-1 antagonists and uses thereof nlrr-1 HK1146065A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97689207P 2007-10-02 2007-10-02
PCT/US2008/078474 WO2009046123A2 (en) 2007-10-02 2008-10-01 Nlrr-1 antagonists and uses thereof

Publications (1)

Publication Number Publication Date
HK1146065A1 true HK1146065A1 (en) 2011-05-13

Family

ID=40526943

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11100147A HK1146065A1 (en) 2007-10-02 2011-01-07 Nlrr-1 antagonists and uses thereof nlrr-1

Country Status (8)

Country Link
US (1) US8691222B2 (ko)
EP (1) EP2207805B1 (ko)
JP (1) JP5695905B2 (ko)
AU (1) AU2008308761B2 (ko)
CA (1) CA2699601A1 (ko)
ES (1) ES2502217T3 (ko)
HK (1) HK1146065A1 (ko)
WO (1) WO2009046123A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009110383A1 (ja) * 2008-03-04 2009-09-11 久光製薬株式会社 癌の治療薬のスクリーニング方法
EP3793603A4 (en) * 2018-05-16 2022-01-26 Chang Gung Memorial Hospital, Linkou NEW LRRN1 (LEUCINE-RICH REPEAT NEURONAL PROTEIN 1) ANTIBODIES AND THEIR USES

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
JPH06507398A (ja) 1991-05-14 1994-08-25 リプリジェン　コーポレーション Ｈｉｖ感染治療のための異種複合抗体
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
DE69334351D1 (de) 1992-02-06 2011-05-12 Novartis Vaccines & Diagnostic Biosynthetisches Bindeprotein für Tumormarker
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
TR200200472T2 (tr) * 1999-08-27 2002-06-21 Genentech, Inc. Anti-Erb B2 antikorları ile tedavi için dozajlar
US7265210B2 (en) * 2000-09-15 2007-09-04 Genentech, Inc. Anti-PRO9821 antibodies
WO2003104438A2 (en) * 2002-06-11 2003-12-18 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy
WO2006130135A1 (en) * 2005-05-31 2006-12-07 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20100028867A1 (en) 2005-10-26 2010-02-04 Elizabeth Bosch LRRTM1 Compositions and Methods of Their Use for the Diagnosis and Treatment of Cancer
AU2007233263A1 (en) * 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
US20070286864A1 (en) * 2006-06-09 2007-12-13 Buck Elizabeth A Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors

Also Published As

Publication number Publication date
JP2010540653A (ja) 2010-12-24
JP5695905B2 (ja) 2015-04-08
ES2502217T3 (es) 2014-10-03
AU2008308761B2 (en) 2014-10-16
CA2699601A1 (en) 2009-04-09
EP2207805A2 (en) 2010-07-21
WO2009046123A2 (en) 2009-04-09
EP2207805B1 (en) 2014-07-09
US20100330082A1 (en) 2010-12-30
AU2008308761A1 (en) 2009-04-09
WO2009046123A3 (en) 2009-06-25
US8691222B2 (en) 2014-04-08

Similar Documents

Publication Publication Date Title
HUS2300039I1 (hu) PSMA-kötõ szerek és alkalmazásaik
HK1203980A1 (en) Il-17ra-il-17rb antagonists and uses thereof il-17ra-il-17rb
IL210506A0 (en) Complement antagonists and uses thereof
IL225521A0 (en) 1trpv antagonists and their uses
TWI561237B (en) Substituted dihydropyrazolones and their use
IL205571A0 (en) 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin
HK1183435A1 (en) Frizzled-binding agents and uses thereof
PT2114900T (pt) Compostos à base de tiopirimidina e as suas utilizações
EP2185692A4 (en) HCO32 AND HCO27 AND RELATED EXAMPLES
ZA200810323B (en) Fkbp-l and uses thereof
IL202752A0 (en) Il-23 receptor antagonists and uses thereof
SI2064327T1 (sl) DBAIT in njegova uporaba
ZA200906812B (en) Crig antagonists
HK1133552A1 (en) Carboranylporphyrins and uses thereof
EP2133326A4 (en) NEW PSEUDOGLYCOLIPID AND ITS USE
EP2209802A4 (en) RESISTANT AGONISTS AND ITS USE
GB201000798D0 (en) Poly-TLR antagonists
HK1146065A1 (en) Nlrr-1 antagonists and uses thereof nlrr-1
GB0708445D0 (en) Compounds and uses thereof
GB0711398D0 (en) Substituted organpolysiloxanes and uses thereof
ZA200906996B (en) TRPV1 Antagonists and uses thereof
IL200459A0 (en) Alpha-halo-and alpha-alkyl-cyclopropylcarboxy compounds and uses thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200927